Flatiron Health is a pioneering health technology company focused on expanding cancer research and improving patient outcomes through real-world data (RWD) applications. Founded in 2012 by Nat Turner, Zach Weinberg, and Gil Addo, the company is based in New York City. It began as a startup dedicated to innovating how electronic health records (EHRs) can be utilized to enhance cancer treatment and research. Flatiron Health has raised approximately $314 million in funding across four rounds from notable investors such as Baillie Gifford and succeeded in being acquired by Roche in 2018 for a valuation of $1.9 billion.
| Attribute | Information |
|---|---|
| Founding Date | 2012 |
| Headquarters | New York City, New York, USA |
| Founders | Nat Turner, Zach Weinberg, and Gil Addo |
| Key Investors | Baillie Gifford, Darwin Ventures |
| Industry | Health Technology, Oncology |
| Number of Employees | Over 1,200 |
Flatiron Health was conceived with the vision to bridge the gap between clinical cancer treatment data and research. Initially, the founders focused on assembling a robust oncology-centric electronic health record system namely OncoEMR. This innovation served as a catalyst in digitally transforming oncology practices and real-world data collection. Over time, Flatiron's emphasis on data reliability and standardization facilitated partnerships with major healthcare stakeholders and pharmaceutical companies. The acquisition by Roche in 2018 was a pivotal point that underscored Flatiron’s prominent status within the healthcare technology sector, accelerating its growth and amplifying its research capabilities globally.
Flatiron Health operates through an innovative business model that combines big data analytics in oncology with scalable software solutions. One of their cornerstone products, OncoEMR, has gained widespread adoption in managing patient records and enhancing precision medicine.
Flatiron Health maintains its status as a leader in real-world evidence for oncology. By integrating data solutions and leveraging cloud-based technologies, it remains at the forefront of transforming cancer care. The company's collaboration with major pharmaceutical players like Abbott allows for enhanced clinical workflows, showcasing its competitive edge in the precision medicine domain. Expanding its international outreach positions Flatiron Health as a vital contributor to global oncology research networks.
Flatiron Health has fundamentally shaped the landscape of healthcare technology through the integration of oncology data, real-world evidence, and advanced analytics. As it continues to expand its influence, particularly in precision medicine and global research collaborations, its potential to further enhance cancer care and facilitate breakthrough oncology discoveries remains significant. The strategic developments and acquisitions underscore the company's commitment to revolutionizing healthcare research and delivery for better patient outcomes in oncology.
